

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.
Form 6-K
March 03, 2008

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of February 2008

AETERNA ZENTARIS INC.

1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F / / Form 40-F /X/

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes / / No /X/

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-___

DOCUMENTS INDEX

DOCUMENTS DESCRIPTION

1. Press Release dated February 28, 2008: AEterna Zentaris to Announce Fourth
Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008

[LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aeternazentaris.com

PRESS RELEASE
For immediate release

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

AETERNA ZENTARIS TO ANNOUNCE FOURTH QUARTER AND FULL-YEAR 2007 FINANCIAL AND OPERATING RESULTS ON MARCH 5, 2008

QUEBEC CITY, CANADA, FEBRUARY 28, 2008 - AETerna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its fourth quarter and full-year 2007 financial and operating results before market open on Wednesday, March 5, 2008. The Company will host a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 416-644-3425, 514-807-8791 or 800-595-8550. A replay of the webcast will also be available on the Company's website for a period of 30 days.

ABOUT AETERNA ZENTARIS INC.

AETerna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

-30-

CONTACTS

Jenene Thomas
Senior Director, Investor Relations & Corporate Communications
(908) 626-5509
jthomas@aezsinc.com

Paul Burroughs
Media Relations
(418) 652-8525 ext. 406
pburroughs@aezsinc.com

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: February 29, 2008

By: /s/Mario Paradis

Mario Paradis
Senior Vice President, Administrative and
Legal Affairs and Corporate Secretary